Nightstar Therapeutics plc (NITE): Bullish Rating Reiterated

NITE – Wedbush reiterates Outperform rating, $31 PT. This price target represents a 114.09% upside over the stock’s previous closing price of $14.48.


Update: As of Dec. 7, 2018, this bullish analyst call has returned -6.84%.


Key Facts Surrounding This News Item


  • NITE had returned +10.37% year-to-date leading up to today’s news, versus a +2.26% return from the benchmark S&P 500 during the same period.

More Info About Nightstar Therapeutics plc (NITE)


Nightstar Therapeutics Limited, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. The company was founded in 2013 and is based in London, the United Kingdom. View our full NITE ticker page with ratings, news, and more.

NITE at a Glance

NITE Current POWR Rating™
Overall POWR Rating™
NITE Current Price $13.49 2.88%
More NITE Ratings, Data, and News

NITE Price Reaction

The day of this event (Mar. 7, 2018)
NITE Closing Price$14.19 2.00%
NITE Volume12,500
84.75% from avg
Leading up to this event
NITE 1-mo return5.77%
After this event
NITE 1-day return3.06%
NITE 3-day return6.47%
NITE 5-day return14.20%

NITE Price Chart


The Top Stocks For 2019

More Nightstar Therapeutics plc (NITE) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All NITE News
Page generated in 0.887 seconds.